Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 6;60(47):6007-6010.
doi: 10.1039/d4cc01788a.

Enantioselective de novo synthesis of 14-hydroxy-6-oxomorphinans

Jonathan C Moore  1   2 , Louis Modell  3 , Jacqueline R Glenn  4   5 , Kieran D Jones  1   2 , Stephen P Argent  2 , J Robert Lane  4   5 , Meritxell Canals  4   5 , Hon Wai Lam  1   2
Affiliations

Enantioselective de novo synthesis of 14-hydroxy-6-oxomorphinans

Jonathan C Moore et al. Chem Commun (Camb). .

Abstract

The enantioselective de novo synthesis of pharmacologically important 14-hydroxy-6-oxomorphinans is described. 4,5-Desoxynaltrexone and 4,5-desoxynaloxone were prepared using this route and their biological activities against the opioid receptors were measured.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts to declare.

Figures

Scheme 1
Scheme 1. (A) Representative morphinan opioids. (B) Previous methods for the semisynthesis of 14-hydroxy-6-oxomorphinans without an E-ring.
Scheme 2
Scheme 2. (A) Key synthetic steps. (B) Forward synthesis of 14-hydroxy-6-oxymorphinans without an E-ring.
See this image and copyright information in PMC

References

    1. Devereaux A. L. Mercer S. L. Cunningham C. W. ACS Chem. Neurosci. 2018;9:2395–2407. doi: 10.1021/acschemneuro.8b00150. - DOI - PubMed
    2. Chambers S. A. DeSousa J. M. Huseman E. D. Townsend S. D. ACS Chem. Neurosci. 2018;9:2307–2330. doi: 10.1021/acschemneuro.7b00528. - DOI - PMC - PubMed
    3. Olson M. E. Eubanks L. M. Janda K. D. J. Am. Chem. Soc. 2019;141:1798–1806. doi: 10.1021/jacs.8b09756. - DOI - PMC - PubMed
    1. World Health Organisation (WHO). “WHO Model List of Essential Medicines – 23rd list, 2023’’ (Publication WHO/MHP/HPS/EML/2023.02, WHO, 2023; https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02)
    1. Furst S. Hosztafi S. Acta Physiol. Hung. 2008;95:3–44. doi: 10.1556/APhysiol.95.2008.1.1. - DOI - PubMed
    2. Feinberg A. P. Creese I. Snyder S. H. Proc. Natl. Acad. Sci. U. S. A. 1976;73:4215. doi: 10.1073/pnas.73.11.4215. - DOI - PMC - PubMed
    1. Revesz L. Siegel R. A. Buescher H. H. H. Marko M. Maurer R. Meigel H. Helv. Chim. Acta. 1990;73:326–336. doi: 10.1002/hlca.19900730212. - DOI
    2. Zhang A. Li F. Ding C. Yao Q. Knapp B. I. Bidlack J. M. Neumeyer J. L. J. Med. Chem. 2007;50:2747–2751. doi: 10.1021/jm0701674. - DOI - PubMed
    3. Li F. Gaob L. Yin C. Chen J. Liu J. Xie X. Zhang A. Bioorg. Med. Chem. Lett. 2009;19:4603–4606. doi: 10.1016/j.bmcl.2009.06.093. - DOI - PubMed
    4. Li F. Yin C. Chen J. Liu J. Xie X. Zhang A. Chem. Biol. Drug Des. 2009;74:335–342. doi: 10.1111/j.1747-0285.2009.00849.x. - DOI - PubMed
    1. Yamamoto N. Fujii H. Nemoto T. Nakajima R. Momen S. Izumimoto N. Hasebe K. Mochizuki H. Nagase H. Bioorg. Med. Chem. Lett. 2011;21:4104–4107. doi: 10.1016/j.bmcl.2011.04.147. - DOI - PubMed
    2. Osa Y. Ida Y. Fujii H. Nemoto T. Hasebe K. Momen S. Mochizuki H. Nagase H. Chem. Pharm. Bull. 2007;55:1489–1493. doi: 10.1248/cpb.55.1489. - DOI - PubMed

MeSH terms